• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Erenumab linked to decreased episodic migraine frequency: The STRIVE trial

byShani ChibberandDayton McMillan
December 1, 2017
in Chronic Disease, Emergency, Neurology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Monthly injections of erenumab were associated with reduced migraine frequency, decreased use of acute migraine medication, and decreased migraine burden on daily activities compared to placebo among patients with episodic migraines.

2. The overall safety profile of erenumab in this trial was comparable to placebo with regards to the types and severity of adverse events assessed.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Migraines pose a significant burden on the quality of life of adults affected. Many currently approved acute migraine-specific medications are either abortive or are cited as having poor treatment adherence, unwanted side effects, or reduced effectiveness. Erenumab, a calcitonin gene-related peptide (CGRP) receptor modulator, is being evaluated as a new potential preventative treatment option for adults with migraine activity. In the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) trial, a 6-month course of erenumab was compared to placebo in a population of patients with episodic migraine activity. The primary endpoint was change in the mean number of migraine days per month from baseline to months 4-6 of treatment. Overall, researchers found significant reductions in the mean number of migraine days per month in the erenumab group compared to placebo, suggesting that erenumab may be a useful therapy for the prevention of episodic migraines. Further studies on the safety and long-term effects of erenumab need to be conducted to further elucidate its role in migraine treatment.

Click to read the study, published in NEJM

Relevant Reading: CGRP, a target for preventative therapy in migraine and cluster headache: Systematic review of clinical data

In-Depth [randomized controlled trial]: This multinational phase 3 randomized controlled study included 955 adults patients with episodic migraine into three treatment arms: 70 mg erenumab (n = 317), 140 mg erenumab (n = 319), or placebo (n = 319) groups. Each arm received monthly subcutaneous injections of their assigned treatment arm. The primary endpoint was change in mean number of migraine days from baseline to the studies end and key secondary endpoints included changes in the number of days of acute migraine-specific medication use, evidence of 50% or greater reduction in the number of mean migraine days per month, and changes in physical-impairment and daily functioning from baseline to the final three months of treatment. The reduction of mean migraine days per month was 3.2 days in the 70 mg erenumab treatment group (95%CI, -1.9 to -0.9; p < 0.001) and 3.7 days in the 140 mg erenumab group (95%CI, -2.3 to -1.4; p < 0.001) compared to 1.8 days in the placebo group. The odds of having a 50% or greater reduction in migraine activity was 2.13 in the 70 mg erenumab group (OR, 1.52 to 2.98; p < 0.001) and 2.81 in the 140 mg erenumab group (OR, 2.01 to 3.94; p < 0.001) compared to placebo. Fewer mean number of days patients used acute migraine-specific medications per month was seen in the treatment arms (1.1 fewer days with 70 mg erenumab, 1.6 with 140 mg erenumab, 0.2 with placebo; p < 0.001 for each arm vs placebo). Improvements in physical-impairment and daily functioning were significantly greater in both treatment arms compared to placebo (p < 0.001 for both comparisons). Serious adverse events occurred 7, 8, and 7 times in the placebo, 70 mg treatment, and 140 mg treatment arms, respectively. The most common reported adverse events across all study arms included nasopharyngitis and upper respiratory infection. Of 628 patients who were tested for antibodies, 35 (5.6%) tested positive for anti-erenumab antibodies (8.0% in the 70 mg group, 3.2% in the 140 mg group).

Image: PD

RELATED REPORTS

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

Atogepant effective in reducing migraine and headache days

More omega-3 and less omega-6 fatty acid consumption associated with reduced migraine frequency and severity

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: erenumabmigraine
Previous Post

Fremanezumab reduces headache frequency in patients with chronic migraine

Next Post

Non-alcoholic fatty liver disease associated with brain volume loss in middle-aged individuals

RelatedReports

Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Emergency

New migraine-specific pharmacologic agents associated with less efficacy compared to triptans

October 11, 2021
Patients report persistent quality-of-life impairments following ruptured brain aneurysms
Chronic Disease

Atogepant effective in reducing migraine and headache days

October 4, 2021
Galcanezumab reduces the frequency of episodic cluster headaches
Neurology

More omega-3 and less omega-6 fatty acid consumption associated with reduced migraine frequency and severity

September 3, 2021
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

September 2, 2021
Next Post
Spleen elastography may be effective in the diagnosis of portal hypertension

Non-alcoholic fatty liver disease associated with brain volume loss in middle-aged individuals

AAP supports limits on juice consumption in pediatric diet

Parents report greater optimism than oncologists about their child’s cancer prognosis

AAP reaffirms support for adolescents’ rights to confidential reproductive care

Multiple treatment trajectories exist in adolescent depression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Subthreshold micropulse laser is equivalent to standard laser for treating diabetic macular edema
  • Gadolinium-containing contrast associated with nephrogenic fibrosing dermopathy and systemic fibrosis [Classics Series]
  • Study supports continued use of amoxicillin as first-line therapy for pediatric ear infections
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.